|
Nxstage Medical, Inc. (NXTM) Files Form 4 Insider Selling : Joseph E Jr Turk ... - Insider Trading Report |
 |
 |
|
Nxstage Medical, Inc. (NXTM): Joseph E Jr Turk , President of Nxstage Medical, Inc. sold 2,839 shares on Jun 10, 2015. The Insider selling transaction was disclosed on Jun 10, 2015 to the Securities and Exchange Commission. The shares were sold at $16.00 per share for a total value of $45,424.00.
According to the SEC Form-4 filing, the Company has disclosed other insider buying and selling activities, The Securities and Exchange Commission has divulged that Turk Joseph E Jr, (President) of Nxstage Medical, Inc., had unloaded 2,000 shares at an average price of $16.64 in a transaction dated on May 26, 2015. The total value of the transaction was worth $33,280. The company shares have rallied 14.61% from its one year high price. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $17.32 and the 200 day moving avarge is recorded at $17.63. S&P 500 has rallied 7.25% during the last 52-weeks. 12.08% of the shares are held by the company Insiders, 91.2% of the shares are held by the institutions. Company shares has an average 3 month share volume of 486,912 and an average 10 day volume is recorded to be 459,425 Shares of NxStage Medical, Inc. (NASDAQ:NXTM) ended Monday session in red amid volatile trading. The shares closed down 0.15 points or 0.94% at $15.85 with 375,762 shares getting traded. Post opening the session at $15.99, the shares hit an intraday low of $15.76 and an intraday high of $16.11 and the price vacillated in this range throughout the day. The company has a market cap of $1,002 million and the number of outstanding shares has been calculated to be 63,238,000 shares. The 52-week high of NxStage Medical, Inc. (NASDAQ:NXTM) is $19.63 and the 52-week low is $11.5. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
|
|
Greater decline in renal function with warfarin in A-fib - Medical Xpress |
|
|
(HealthDay)—For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin versus dabigatran etexilate (DE), according to a study published in the June 16 issue of the Journal of the American College of Cardiology.
Michael Böhm, M.D., from the Universitätsklinikum des Saarlandes in Homburg, Germany, and colleagues examined changes in glomerular filtration rate (GFR) during long-term treatment with warfarin or DE in 18,113 patients enrolled in the Randomized Evaluation of Long Term Anticoagulation Therapy trial. Participants were randomized to DE (110 mg or 150 mg twice daily) or warfarin and followed for up to 30 months.
The researchers observed a decrease in GFR in all treatment groups. The mean decline in GFR was significantly greater with warfarin (?3.68 ml/min) versus DE 110 mg (?2.57 ml/min; P = 0.0009 versus warfarin) or DE 150 mg (?2.46 ml/min; P = 0.0002 versus warfarin), after an average of 30 months. In the observation period >18 months, the likelihood of a decrease in GFR >25 percent was lower with DE 110 mg (hazard ratio, 0.81; P = 0.017) or DE 150 mg (hazard ratio, 0.79; P = 0.0056) versus warfarin. The decline in GFR was more pronounced with previous warfarin use and presence of diabetes.
"Patients with atrial fibrillation receiving oral anticoagulation exhibited a decline in renal function that was greater in those taking warfarin versus DE, and it was amplified by diabetes and previous vitamin K antagonist use," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
 Explore further: Post-CABG predictors of stroke identified for diabetes patients More information: Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal reference: Journal of the American College of Cardiology 4 shares Copyright © 2015 HealthDay. All rights reserved.
|
|
|
Dialysis Market Global Research Trends, Size, Segments And Opportunities ... - Medgadget.com (blog) |
|
|
Global Dialysis MarketReport: 2015 Edition provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis/245499
Dialysis is the artificial process of eliminating waste and unwanted water from the blood. It is carried out by using a special fluid called dialysate, a mixture of pure water and chemicals, is carefully controlled to pull wastes out of your blood without removing substances your body needs. There are two types of dialysis: hemodialysis and peritoneal dialysis. Hemodialysis removes wastes and water by circulating blood outside the body through an external filter, called a dialyzer and in peritoneal dialysis, wastes and water are removed from the blood inside the body using the peritoneum as a natural semipermeable membrane.
End stage renal disease (ESRD) is the last stage of chronic kidney disease. This is the situation when kidney is functioning below 10% of their normal function and they can no longer support a person’s day to day life. The common causes of ESRD include high blood pressure, atherosclerosis, and genetic disorders. ESRD treatment is carried out either by dialysis or kidney transplant.
The report analyzes the global and regional dialysis markets. Some of the factors driving the growth of dialysis market include: growing number of diabetic patients, increasing dialysis population and incidences of chronic and infectious diseases which has further increased the healthcare expenditure and pharmaceutical sales. Market dynamics like key trends and development, challenges and growth drivers are discussed in detail. The key players having the vicious competition with each other are: DaVita, Baxter, and Fresenius. These players are being profiled in the report along with their key financials and strategies for growth.
Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/245499
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the market. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
To View The Top Related News: http://www.marketresearchreports.biz/articles
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Mail To:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Thanks………..!!!!!!!!!!!
|
|
Bladen County man celebrates 2500 dialysis treatments - WECT-TV6 |
|
|
|
BLADEN COUNTY, NC (WECT) -
This week marks a unique milestone for a Bladen County man. On Monday, Marvin Burney received his 2,500th dialysis treatment. He celebrated with cake.
It's a rare celebration. The average life expectancy on dialysis is 5-10 years.
Burney has now been on dialysis for 20 years, much of it is done at home.
"I put in about 15 hours a week doing dialysis and taking care of my machine," Burney says. "That's not a bad trade-off for all of the other hours in the week when I'm very 'normal' and have a very good life."
He discovered his kidney problems in 1995.
"I thought I had a bad case of the flu, but I never could shake it," Burney says.
He was in complete kidney failure.
"I had my first dialysis treatment four days later at Duke Hospital," he says.
In July of 2000, he received his first kidney transplant. His donor was no stranger. It was his wife, Marsha. While she was a match, doctors at Duke said she was a 'low match." Still, they rolled the dice.
"Against the odds, this transplant contracted the same disease that destroyed my original kidneys," Burney says.
The transplant was short-lived. By 2003, he was back on dialysis. He would continue to get the treatments for 7 1/2 years until receiving a second kidney, this time from a stranger. It was from a young man who died as a registered donor.
"It was a 'perfect match' kidney, and I was very lucky," Burney says. I had this kidney for 4 1/2 years before I lost it this past January."
The same disease that claimed his original kidneys and the one from his wife, destroyed his second transplant. Just recently, he was denied the chance to sign up for a third.
Burney says while he's disappointed, dialysis is not a way of life for him, rather a small part of it.
Burney says he hopes the snapshot of his celebration of 2500 treatments will not be a deterrent to someone just learning that they have kidney disease, rather a sign of hope.
"Most importantly, dialysis is NOT, NOT, NOT a 'death sentence.' It is a chance for a little more LIFE. Make it a quality life and keep a positive attitude."
Copyright 2015 WECT. All rights reserved.
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
